Prelude Capital Management, LLC Cyma Bay Therapeutics, Inc. Transaction History

Prelude Capital Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$5.88 - $9.59 $64,521 - $105,231	10,973 New	10,973 $95,000
Q3 2019 Nov 14, 2019	SELL	$5.12 - $7.21 $3,927 - $5,530	-767 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$6.05 - $13.66 $4,640 - $10,477	767 New	767 $5,000
Q1 2019 May 15, 2019	SELL	$8.16 - $13.42 $7,384 - $12,145	-905 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$6.54 - $11.74 $621 - $1,115	95 Added 11.73%	905 $7,000
Q3 2018 Nov 14, 2018	BUY	$10.88 - $14.52 $8,812 - $11,761	810 New	810 $9,000
Q2 2018 Aug 14, 2018	SELL	$10.66 - $14.38 $9,657 - $13,028	-906 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$9.0 - $15.16 $3,744 - $6,306	416 Added 84.9%	906 $12,000
Q4 2017 Feb 14, 2018	SELL	$7.67 - $9.31 $50,698 - $61,539	-6,610 Reduced 93.1%	490 $5,000
Q3 2017 Nov 14, 2017	BUY	$5.95 - $8.26 $42,245 - $58,646	7,100	7,100 $57,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.